Effects of selenium in patients with autoimmune thyroiditis

Elena A. Shabalina; Valentin V. Fadeyev

doi:10.14341/ket10299

Effects of selenium in patients with autoimmune thyroiditis

Elena A. Shabalina, Valentin V. Fadeyev

https://doi.org/10.14341/ket10299

Full Text:

PDF (Rus) HTML (Rus) XML (Rus)

Generate QR code

Abstract

Background: In the last decades, a number of clinical studies have been conducted where both the positive and neutral effects of Se on thyroid autoimmunity have been demonstrated.

Aims: The aim of our study was to assess the effects of selenmethionine among euthyroid patients with elevated TPO-Ab (TPO > 100 IU/ml) and patients with subclinical hypothyroidism and elevated TPO-Ab.

Materials and methods: 40 euthyroid patients with elevated TPO-Ab and 11 patients with subclinical hypothyroidism plus elevated TPO-Ab were included in our study. Patients of both categories were randomized to recieve Se 200 μg/day or to the dynamic observation. TSH, f. T4, f. T3, AT-TPO were measured at baseline and every 3 months of follow-up. The volume and echogenicity of the thyroid were also evaluated every 3 month of follow-up period (12 month).

Results: There were no significant difference between the groups on the dynamics of TSH, f. T3, f. T4, AT-TPO titers, volume and the echogenicity of the thyroid gland during the whole observational period among euthyroid patients with elevated TPO-Ab. Among the patients with subclinical hypothyroidism there were also no significant difference between the groups on the dynamics of f. T3, f. T4, AT-TPO titers, volume and the echogenicity of the thyroid gland during the whole observational period. But by the 12 month of the follow-up there were significantly more euthyroid patients in Se group compare to dynamic observation group.

Conclusions: Our study, failed to show possitive effects of Se supplementation on thyroid autoimmunity.

Keywords

selenium, autoimmune thyroiditis, subclinical hypothyroidism, antibodies against thyroperoxidase

About the Authors

Elena A. Shabalina

First Moscow Medical Setchenov's University, Department of Endocrinology

Russian Federation

Valentin V. Fadeyev

First Moscow Medical Setchenov's University, Department of Endocrinology

Russian Federation

MD, PhD, Professor

References

1. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994;15(6):788-830. doi: http://doi.org/10.1210/edrv-15-6-788.

2. Mackenzie WA, Davies TF. An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells. Immunology. 1987;61(1):101-103.

3. Bogner U, Schleusener H, Wall JR. Antibody-dependent cell mediated cytotoxicity against human thyroid cells in Hashimoto’s thyroiditis but not Graves’ disease. J Clin Endocrinol Metab. 1984;59(4):734-738. doi: http://doi.org/10.1210/jcem-59-4-734.

4. Rodien P, Madec AM, Ruf J, et al. Antibody-dependent cell-mediated cytotoxicity in autoimmune thyroid disease: relationship to antithyroperoxidase antibodies. J Clin Endocrinol Metab. 1996; 81(7):2595-2600. doi: http://doi.org/10.1210/jcem.81.7.8675583.

5. Duntas LH. Environmental factors and autoimmune thyroiditis. Nat Clin Pract Endocrinol Metab. 2008;4(8):454-460. doi: http://doi.org/10.1038/ncpendmet0896.

6. Duntas LH. The role of iodine and selenium in autoimmune thyroiditis. Horm Metab Res. 2015;47(10):721-726. doi: http://doi.org/10.1055/s-0035-1559631.

7. Mazokopakis EE, Papadakis JA, Papadomanolaki MG, et al. Effects of 12 months treatment with l-selenomethionine on serum anti-TPO levels in patients with Hashimoto’s thyroiditis. Thyroid. 2007;17(7):609-612. doi: http://doi.org/10.1089/thy.2007.0040.

8. Duntas LH, Mantzou E, Koutras DA. Effects of a six month treatment with selenomethionine in patients with autoimmune thyroiditis. Eur J Endocrinol. 2003;148(4):389-393. doi: http://doi.org/10.1530/eje.0.1480389.

9. Karanikas G, Schuetz M, Kontur S, et al. No immunological benefit of selenium in consecutive patients with autoimmune thyroiditis. Thyroid. 2008;18(1):7-12. doi: http://doi.org/10.1089/thy.2007.0127.

10. Gärtner R, Gasnier BC, Dietrich JW, et al. Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations. J Clin Endocrinol Metab. 2002;87(4):1687-1691. doi: http://doi.org/10.1210/jcem.87.4.8421.

11. Wichman J, Winther KH, Bonnema SJ, Hegedüs L. Selenium supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis. Thyroid. 2016;26(12):1681-1692. doi: http://doi.org/10.1089/thy.2016.0256.

12. Winther KH, Watt T, Bjørner JB, et al. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials. 2014;15:115. doi: http://doi.org/10.1186/1745-6215-15-115.

13. Negro R, Attanasio R, Grimaldi F, et al. A 2016 Italian survey about clinical use of selenium in thyroid disease. Eur Thyroid J. 2016;5(3):164-170. doi: http://doi.org/10.1159/000447667.

14. Negro R, Hegedüs L, Attanasio R, et al. A 2018 European thyroid association survey on the use of selenium supplementation in Graves’ hyperthyroidism and Graves’ orbitopathy. Eur Thyroid J. 2019;8(1):7-15. doi: http://doi.org/10.1159/000494837.

15. Шабалина Е.А., Фадеев В.В. Эффекты селена в составе консервативной терапии болезни Грейвса // Клиническая и экспериментальная тиреоидология. – 2016. – Т.12. – №4. – С. 16-30. [Shabalina EA, Fadeyev VV. Effects of selenium in patients with Graves’ disease treated with antithyroid drugs. Clinical and experimental thyroidology. 2016;12(4):16-30. (In Russ.)] doi: http://doi.org/10/14341/ket2016416-30.

Supplementary files

	1. Fig. 1. Research design.
	Subject
	Type	Other
	View (115KB)	Indexing metadata ▾

	2. Fig. 2. TSH level during 12 months of observation in the main and control groups of carriers of AT-TPO (here and in the following figures, the main group is highlighted in light, and the control group in dark).
	Subject
	Type	Other
	View (166KB)	Indexing metadata ▾

	3. Fig. 3. Dynamics of AT-TPO indicators during 12 months of observation in carriers of AT-TPO.
	Subject
	Type	Other
	View (182KB)	Indexing metadata ▾

	4. Fig. 4. Dynamics of TSH level during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Subject
	Type	Other
	View (156KB)	Indexing metadata ▾

	5. Fig. 5. Dynamics of AT-TPO indicators during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Subject
	Type	Other
	View (176KB)	Indexing metadata ▾

	6. Fig. 6. Change in thyroid volume during 12 months of observation in carriers of AT-TPO.
	Subject
	Type	Other
	View (159KB)	Indexing metadata ▾

	7. Fig. 7. Change in thyroid volume during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Subject
	Type	Other
	View (154KB)	Indexing metadata ▾

Review

For citations:

Shabalina E.A., Fadeyev V.V. Effects of selenium in patients with autoimmune thyroiditis. Clinical and experimental thyroidology. 2019;15(2):44-54. (In Russ.) https://doi.org/10.14341/ket10299

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).

ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

	Title	Fig. 1. Research design.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4245

	Title	Fig. 2. TSH level during 12 months of observation in the main and control groups of carriers of AT-TPO (here and in the following figures, the main group is highlighted in light, and the control group in dark).
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4246

	Title	Fig. 3. Dynamics of AT-TPO indicators during 12 months of observation in carriers of AT-TPO.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4247

	Title	Fig. 4. Dynamics of TSH level during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4248

	Title	Fig. 5. Dynamics of AT-TPO indicators during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4249

	Title	Fig. 6. Change in thyroid volume during 12 months of observation in carriers of AT-TPO.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4250

	Title	Fig. 7. Change in thyroid volume during 12 months of observation in patients with subclinical hypothyroidism and AT-TPO carriage.
	Date	2019-07-29
Digital Object Identifier	https://doi.org/10.14341/ket10299-4251

User

Clinical and experimental thyroidology

Effects of selenium in patients with autoimmune thyroiditis

Full Text:

Abstract

Keywords

About the Authors

References

Supplementary files

Review

For citations:

Cookies policy